|Bid||41.720 x 800|
|Ask||41.730 x 900|
|Day's Range||41.390 - 41.825|
|52 Week Range||35.100 - 45.090|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.03|
As Breast Cancer Awareness Month kicks off, Hologic CEO Steve MacMillan speaks to "Squawk Box" about the company's new imaging tech to better help detect cancer.
Hologic, Inc. (HOLX) announced today that Ludwig N. Hantson has been elected to the Company’s Board of Directors, effective immediately. Dr. Hantson, who has more than 30 years of experience in the life sciences industry, is the Chief Executive Officer of Alexion Pharmaceuticals, Inc., a publicly-traded global biopharmaceutical company. Before joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated.
Hologic, Inc. announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28 at 8 a.m.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Hologic (HOLX) delivered earnings and revenue surprises of -1.69% and 1.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
MARLBOROUGH, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported fiscal fourth-quarter profit of $50.5 million. The Marlborough, Massachusetts-based company said it had profit of 18 cents per share. The results fell short of Wall Street expectations.
Hologic, Inc. announced today that the Company will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 at 8 a.m. Eastern Time.
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In this article I am going to calculate the intrinsic value of Hologic Inc (NASDAQ:HOLX) by projecting its future cash flows and then discounting them to today’s value. I will Read More...
Hologic, Inc. announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2018 on Wednesday, November 7, 2018, after the market closes.
Survey commissioned by Company behind the Genius™ 3D Mammography™ exam sheds light on need for education during Breast Cancer Awareness Month MARLBOROUGH, Mass. , Oct. 1, 2018 /PRNewswire/ -- WHO: ...
Hologic, Inc. (HOLX) announced today that Nancy G. Brinker, global cancer advocate, Hologic consultant and founder of Susan G. Komen, and Krystal Barter, author and founder of Australian nonprofit Pink Hope, will join Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, and selected employees to ring the Nasdaq Opening Bell for the 13th consecutive year on October 1 to mark the start of Breast Cancer Awareness Month. In addition to appearing at the Nasdaq MarketSite, Hologic will recognize Breast Cancer Awareness Month by announcing the results from their recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the effect it has on breast cancer screening and cancer detection.
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 26) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic’s recent acquisition of Faxitron Bioptics, Focal strengthens the Company’s position in the rapidly growing market for breast conserving surgery. The transaction adds Focal’s innovative BioZorb marker to the Company’s Breast Health product portfolio.